The latest information about BioMark Diagnostics to keep you up to date.
BioMark Diagnostics is leading the world in early-stage cancer detection with an oncology focus designed to improve patient outcomes.
BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung
BioMark’s Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost
BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test
BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing
BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum BioMark
BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection
BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors Expanding U.S. market
BioMark: 2025 Achievements & 2026 Vision Celebrating A Year of Extraordinary Achievement VANCOUVER, BRITISH COLUMBIA
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program Company engages Standards Council
No paperwork, no hassle. We keep things digital, easy and regular.
*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.
1 604 370 0779
130 3851 Shell Road
Richmond BC
Canada V6X 2W2
Rashid A. Bux (CEO)
[email protected]